Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General…
Categorie
2022
MaaT Pharma Announces Update on U.S. FDA Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease Lyon,…
August 10, 2022
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General…
August 1, 2022
MaaT Pharma Reports Cash and Revenues for Second Quarter 2022 As of June 30, 2022, cash and cash equivalents were…
July 28, 2022
MaaT Pharma Announces the Availability of the 2021 Universal Registration Document Lyon, France, July 6, 2022, 6:00 pm CET –…
July 6, 2022
MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients Data describe rapid,…
June 2, 2022
MaaT Pharma to Host First Virtual R&D Day on June 7th, 2022 R&D Day will take place virtually on June…
May 24, 2022
MaaT Pharma Announces Combined General Meeting on May 31, 2022 and the Availability of the Preparatory Documents Lyon, France, May…
May 10, 2022
MaaT Pharma Announces Resignation of an Independent Board Member Lyon, France, May 10th, 2022 – 6:05pm CET – MaaT Pharma…
May 10, 2022
MaaT Pharma Reports Cash and Revenues for first quarter 2022 As of March 31, 2022, cash and cash equivalents of…
May 5, 2022
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.